Related Experiment Video
Updated: Feb 12, 2026
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
14.0K
Hepatitis-associated Aplastic Anemia Treated Successfully With Antithymocyte Globulin
Hongyan Ji1, Li Chen2, Xiaojun Sun1
1Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, Shandong.
Journal of Pediatric Hematology/Oncology
|April 6, 2018
Summary
Hepatitis-associated aplastic anemia (HAAA) is a rare, lethal condition in children. Successful treatment was achieved using immunosuppressive therapy in a young boy, offering hope for similar cases.
Area of Science:
- Pediatric Hematology
- Hepatology
- Immunology
Background:
- Hepatitis-associated aplastic anemia (HAAA) is a severe bone marrow failure syndrome.
- It typically follows seronegative hepatitis, predominantly affecting male children.
- Untreated HAAA has a high mortality rate.
Purpose of the Study:
- To report a successful treatment of HAAA in a pediatric patient.
- To highlight the efficacy of immunosuppressive therapy for HAAA.
Main Methods:
- Case report of a 3-year-old boy diagnosed with HAAA.
- Treatment administered included immunosuppressive therapy.
Main Results:
- The patient achieved successful treatment outcomes.
- The chosen therapy effectively managed the bone marrow failure.
Conclusions:
- Immunosuppressive therapy is a viable and effective treatment option for HAAA in children.
- This case demonstrates a positive response to immunosuppression in a life-threatening condition.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
01:21Hepatic Portal System
6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
248
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
01:16Hepatic Drug Excretion: Influencing Factors
599
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
599
01:14Hepatic Drug Clearance: Role of Transporters
311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311
01:17Hepatic Drug Excretion: Enterohepatic Cycling
2.9K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.9K